Episode 24 - Rademikibart therapy for AD: a Chinese randomized trial

In this episode of BJD Talks, Sam and Meera discuss the article ‘Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (SEASIDE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing’ by Zhang et al. The full article can be accessed at https://doi.org/10.1093/bjd/ljaf346 

*This podcast was generated by an AI tool created by 67Bricks for the British Association of Dermatologists* 

Transcript

SPEAKER_01 0:00

Welcome to BJD Talks, the official podcast of the BJD. I'm Sam.

SPEAKER_00 0:04

And I'm Mira. In this episode, we will be discussing the article by Jianjong Jange Al, Radamiki Bart Monotherapy for Moderate to Severe Atopic Dermatitis in a one-year randomised phase two trial, Seaside China, published in September 2025 and included in the January 2026 issue.

SPEAKER_01 0:24

Mira, this study offers some intriguing insights. For those tuning in, we're exploring new developments in managing moderate to severe atopic dermatitis or AD. It's a chronic condition that can cause distressing symptoms such as painful flare-ups, severe itching, disrupted sleep, and even mental health issues.

SPEAKER_00 0:43

Exactly. And for patients with severe AD, standard treatments often fall short. That's where biologics like radamicybart could make a real difference. This monoclonal antibody targets the interleukin-4 receptor alpha with high specificity, essentially blocking a key inflammatory pathway in AD.

SPEAKER_01 1:03

Indeed, RadamikiBart is still in clinical development and has not received regulatory approval as of the date of this episode. However, the Seaside China trial assessed the efficacy and safety of Radamikibar in Chinese adults and adolescents over one year. The trial was in two stages. Stage 1 focused on short-term results over 16 weeks, while stage 2 extended treatment for another 36 weeks.

SPEAKER_00 1:28

And the findings were impressive. In stage 1, patients receiving Radamikibar bi-weekly through subcutaneous injections saw significant improvements. By week 16, nearly 29% achieved a score of zero or one on the validated investigator global assessment scale, meaning clear or nearly clear skin, compared to just under 6% in the placebo group.

SPEAKER_01 1:53

Substantial results. Additionally, about 58.6% of patients on RadamikiBart achieved at least a 75% improvement in their eczema area and severity index, or easy 75% versus 22.6% with placebo. Pareto's severity also improved, with over 36% of patients reporting a reduction of 4 points or more.

SPEAKER_00 2:16

Stage 2 built on this. Patients were reassigned to either fortnightly or monthly dosing, and results remained consistent. Over 84% achieved Easy 75 by week 52. Most impressively, nearly 90% maintained their improvements until the end of the study.

SPEAKER_01 2:41

Safety was also reassuring. The most common side effects were mild injection site reactions, and no serious treatment-related adverse events occurred. Of course, three patients withdrew due to unrelated issues like pregnancy, a flare-up of eczema, and a case of vitiligo.

SPEAKER_00 2:58

The safety profile is encouraging. Comparatively, dupilimab is currently the only approved systemic biologic for AD in China. While effective, it requires fortnightly dosing and may plateau in benefits by week 16, so RadamikiBart has clear advantages.

SPEAKER_01 3:15

Agreed. Its sustained efficacy and less frequent dosing could set it apart. Nevertheless, as a phase two trial, it has its limitations, particularly in terms of sample size and geographic scope. Larger global phase three trials will be crucial to confirm its broader applicability.

SPEAKER_00 3:32

And we must also consider cost and accessibility. Will RadamikiBart be affordable compared to existing biologics? And will patients in resource-limited settings have access to it?

SPEAKER_01 3:43

Important questions, indeed. But as it stands, RadamikiBart offers a promising combination of quick relief, long-lasting results, and fewer injections. Potentially a game changer for moderate to severe AD management.

SPEAKER_00 3:58

Absolutely. It could provide dermatologists with a more effective and convenient treatment option. Thanks for joining us on BJD Talks, and we look forward to bringing you more discussions on innovative dermatology advances next time.

SPEAKER_01 4:12

Until then, take care and stay curious.